Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Dow
Boehringer Ingelheim
AstraZeneca
Express Scripts

Last Updated: May 19, 2022

ZUPLENZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Zuplenz, and when can generic versions of Zuplenz launch?

Zuplenz is a drug marketed by Aquestive and is included in one NDA. There are two patents protecting this drug.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zuplenz

A generic version of ZUPLENZ was approved as ondansetron by MYLAN on June 25th, 2007.

  Try it Free

Summary for ZUPLENZ
International Patents:18
US Patents:2
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 123
Clinical Trials: 5
Patent Applications: 4,026
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ZUPLENZ
What excipients (inactive ingredients) are in ZUPLENZ?ZUPLENZ excipients list
DailyMed Link:ZUPLENZ at DailyMed
Drug patent expirations by year for ZUPLENZ
Drug Prices for ZUPLENZ

See drug prices for ZUPLENZ

Recent Clinical Trials for ZUPLENZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
M.D. Anderson Cancer CenterPhase 2
Tesaro, Inc.Phase 2

See all ZUPLENZ clinical trials

US Patents and Regulatory Information for ZUPLENZ

ZUPLENZ is protected by two US patents.

Patents protecting ZUPLENZ

Non-mucoadhesive film dosage forms
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stabilized amine-containing actives in oral film compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aquestive ZUPLENZ ondansetron FILM;ORAL 022524-001 Jul 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive ZUPLENZ ondansetron FILM;ORAL 022524-002 Jul 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive ZUPLENZ ondansetron FILM;ORAL 022524-001 Jul 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive ZUPLENZ ondansetron FILM;ORAL 022524-002 Jul 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZUPLENZ

See the table below for patents covering ZUPLENZ around the world.

Country Patent Number Title Estimated Expiration
Hungary E038022 See Plans and Pricing
European Patent Office 2444072 Formes galéniques de film non mucoadhésifs (Non-mucoadhesive film dosage forms) See Plans and Pricing
Brazil PI0719840 FORMAS DE DOSAGEM DE PELÍCULAS NÃO-MUCOADESIVA See Plans and Pricing
New Zealand 575900 NON-MUCOADHESIVE FILM DOSAGE FORMS See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Mallinckrodt
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.